The Purpose of this study is to evaluate the safety and tolerability, and the biological effects of the chimeric anti-CD40 monoclonal antibody Chi Lob 7/4, given intravenously, weekly for 4 weeks in the treatment of patients with advanced malignancies refractory to conventional anti-cancer treatment.

The primary objective of the study is to establish the safety and maximum tolerated dose of Chi Lob 7/4. In line with other established antineoplastic, chimeric monoclonal antibody therapies such as Rituximab, Chi Lob 7/4 will be given by slow intravenous infusion once every week for a total of four weeks. This treatment regimen will facilitate early, rapid and dose dense administration of antibody to a patient group with advanced malignancy refractory to conventional treatment. The starting dose for each infusion of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Escalation from one treatment dose level to another will only be permitted when at least 3 patients have completed treatment without dose limiting toxicity.

Inclusion Criteria:

• Histologically proven CD40 expressing solid tumours or diffuse large B-cell non-Hodgkin"s lymphoma refractory to conventional treatment, or for which no conventional therapy exists.

• Written informed consent and the ability of the patient to co-operate with treatment and follow up must be ensured and documented.

• Age greater than 18 years.

• Life expectancy of at least 12 weeks.

• World Health Organisation (WHO) performance status of 0-1 (Appendix 1).

• Haematological and biochemical indices (These measurements must be performed within one week prior to the patient going on study.)

  • Haemoglobin (Hb) ≥ 9.0 g/dl

  • Neutrophils ≥ 1 x 10^9/L

  • Total Lymphocyte count ≥ 0.5 x 10^9/L

  • Platelets (Plts) ≥ 75 x 10^9/L

  • The following baseline liver function tests :

    • Serum bilirubin ≤ 1.5 x upper limit of normal (ULN)
    • Alanine amino-transferase (ALT) and/or aspartate amino-transferase (AST) ≤ 3 x ULN unless due to tumour in which case up to 5 x ULN is permissible

  • The following baseline renal function test:

    • calculated creatinine clearance ≥ 40 mL/min (uncorrected value) or isotope clearance measurement ≥ 40mL/min

• Female patients of child-bearing potential are eligible, provided they have a negative serum or urine pregnancy test prior to enrolment and agree to use appropriate medically approved contraception for four weeks prior to entering the trial, during the trial and for six months afterwards.

• Male patients must agree to use appropriate medically approved contraception during the trial and for six months afterwards.

Exclusion Criteria:

• CD40 negative tumours by immunohistochemistry.
• Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or chemotherapy during the previous four weeks (six weeks for nitrosoureas and mitomycin-C) prior to treatment.
• All toxic manifestations of previous treatment must have resolved. Exceptions to this are alopecia or certain Grade 1 toxicities which in the opinion of the Investigator and Cancer Research UK should not exclude the patient.
• Pregnant and lactating women are excluded.
• Major thoracic and/or abdominal surgery in the preceding four weeks from which the patient has not yet recovered.
• Patients with primary brain tumours or clinically apparent brain metastases.
• Patients who are high medical risks because of non-malignant systemic disease including active uncontrolled infection.
• Patients with any other condition which in the Investigator"s opinion would not make the patient a good candidate for the clinical trial.
• Patients known to be serologically positive for Hepatitis B, Hepatitis C or Human Immunodeficiency Virus (HIV).
• Long term immunosuppression or steroids (for more than one month)
• History of significant and serious allergy.
• Concurrent congestive heart failure or prior history of class III/ IV cardiac disease (New York Heart Association [NYHA] - refer to Appendix 4)
• Patients with low grade or transformed non-Hodgkin"s lymphoma.
• Prior treatment with murine monoclonal antibodies. (Prior treatment with chimeric or fully human antibodies will not exclude a patient).
• A history of clinically significant autoimmune disease.
• Current malignancies at other sites, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Cancer survivors, who have undergone potentially curative therapy for a prior malignancy, have no evidence of that disease for five years and are deemed at low risk for recurrence, are eligible for the study.